Extended Data Fig. 1: Overview of the trials design. | Nature Medicine

Extended Data Fig. 1: Overview of the trials design.

From: Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Extended Data Fig. 1: Overview of the trials design.The alternative text for this image may have been generated using AI.

a, Trial design of LIBERTY-PN PRIME and b, trial design of LIBERTY-PN PRIME2. *Low-to-medium potency TCS/TCI as background therapy permitted (dose maintained from screening to EOT). †One patient in the placebo group was randomized but not exposed to study intervention due to patient’s decision (fear of being exposed to COVID-19). EOS, end of study; EOT, end of treatment; R, randomization; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids.

Back to article page